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Abstract
Background: The adoption of quadrivalent influenza vaccine (QIV) to replace trivalent influenza vaccine (TIV) in
immunization programs is growing worldwide, thus helping to address the problem of influenza B lineage
mismatch. However, the price per dose of QIV is higher than that of TIV. In such circumstances, cost-effectiveness
analyses provide important and relevant information to inform national health recommendations and implementation
decisions. This analysis assessed potential vaccine impacts and cost-effectiveness of a country-wide switch from TIV to
QIV, in Canada and the UK, from a third-party payer perspective.
Methods: An age-stratified, dynamic four-strain transmission model which incorporates strain interaction, transmission-
rate seasonality and age-specific mixing in the population was used. Model input data were obtained from published
literature and online databases. In Canada, we evaluated a switch from TIV to QIV in the entire population. For the UK,
we considered two strategies: Children aged 2–17 years who receive the live-attenuated influenza vaccine (LAIV)
switch to the quadrivalent formulation (QLAIV), while individuals aged > 18 years switch from TIV to QIV. Two different
vaccination uptake scenarios in children (UK1 and UK2, which differ in the vaccine uptake level) were considered.
Health and cost outcomes for both vaccination strategies, and the cost-effectiveness of switching from TIV/LAIV to QIV/
QLAIV, were estimated from the payer perspective. For Canada and the UK, cost and outcomes were discounted using
5 % and 3.5 % per year, respectively.
Results: Overall, in an average influenza season, our model predicts that a nationwide switch from TIV to QIV would
prevent 4.6 % influenza cases, 4.9 % general practitioner (GP) visits, 5.7 % each of emergency room (ER) visits and
hospitalizations, and 6.8 % deaths in Canada. In the UK (UK1/UK2), implementing QIV would prevent 1.4 %/1.8 % of
influenza cases, 1.6 %/2.0 % each of GP and ER visits, 1.5 %/1.9 % of hospitalizations and 4.3 %/4.9 % of deaths.
Discounted incremental cost-utility ratios of $7,961 and £7,989/£7,234 per quality-adjusted life-year (QALY) gained are
estimated for Canada and the UK (UK1/UK2), both of which are well within their respective cost-effectiveness threshold
values.
Conclusions: Switching from TIV to QIV is expected to be a cost-effective strategy to further reduce the burden of
influenza in both countries.
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Background
Influenza A and B viruses are notable respiratory patho-
gens and remain an important cause of public health
concern worldwide [1, 2], with annual influenza attack
rates ranging from 5–10 % in adults to 20–30 % in chil-
dren [1]. While the influenza B virus has often been
regarded to be milder than influenza A, several studies
have reported that they both cause disease of similar se-
verity, symptoms and rates of influenza-related compli-
cations [3–6]. Influenza A and B both cause annual
epidemics in individuals of all ages, with B accounting
for about a quarter of cases on average, although the
proportion can vary substantially from season to season,
from less than 1 % to over 50 % [2].
Efficacious and safe influenza vaccines remain the
cornerstone of influenza prevention worldwide. Until the
2012–2013 influenza season, only trivalent influenza
vaccines were in use, containing two influenza A strains
(A/H1N1 and A/H3N2) and only one of the two influ-
enza B lineages, B/Victoria and B/Yamagata. As influ-
enza viruses undergo frequent changes in their surface
antigens, the composition of influenza vaccines is chan-
ged annually to match the circulating virus subtype ex-
pected for the next influenza season, based on the
recommendations of the World Health Organization
(WHO) [1, 7]. Because there is limited cross-protection
between the two influenza B lineages [8, 9], the effective-
ness of each season’s trivalent vaccine against influenza
B depends on correct prediction of the circulating B
lineage [10]. With co-circulation of both influenza B lin-
eages in the last decade [2, 7, 8, 10, 11], this has proven
to be challenging; worldwide, the chosen B lineage has
been mismatched to the dominant circulating lineage in
about half of the seasons. As of the 2013–2014 season,
the availability of quadrivalent influenza vaccines, con-
taining both B lineages each season, has offered the po-
tential of improved protection. Indeed, vaccination with
quadrivalent vaccine has shown improved immunogen-
icity, compared with TIV, in children, adults and elderly
people [12–15].
Traditionally, annual seasonal influenza vaccination
has been targeted to people classified as being at high-
risk, particularly the elderly, but in recent years, with in-
creasing evidence in favor of universal vaccination [16],
vaccination recommendations have been expanded to
target larger numbers and diverse population subgroups.
Only some countries now recommend universal influ-
enza immunization. In Canada, publicly-funded univer-
sal influenza immunization programs exist in all
provinces except British Columbia, Quebec and New
Brunswick [17]. The United Kingdom (UK) has until re-
cently had a targeted influenza immunization program
with publicly-funded immunization only for people aged
65 years and over, plus the clinical at-risk population.
However, beginning with the 2013–2014 season, rollout
of a phased extension of the immunization program to
healthy children has commenced [18, 19].
Cost-effectiveness analyses are widely used and ac-
cepted to explore and understand the impact of different
strategies and interventions in diverse settings. Recently
performed cost-effectiveness studies using static cohort
models show that switching from TIV to quadrivalent
influenza vaccine (QIV) in universal programs is a cost-
effective strategy [20–23]. Static models cannot however
fully model the impact of plausible herd effects which
are known to be afforded by vaccination [22, 24]. More-
over, the variability of model outcomes that is attribut-
able to age-specific disease transmission parameters
crucial in understanding infectious diseases has not been
considered [21]. Dynamic transmission models are the
preferred choice when analyzing influenza [25]. The aim
of this modeling study using an age-stratified dynamic
transmission disease model was to assess the public
health and economic impact of a nationwide switch
from TIV to QIV, in Canada and the UK, from the per-
spective of the healthcare provider (third party payer).
Methods
Model overview
We used a previously published compartmental (Suscep-
tible-Infected-Recovered-Vaccinated) dynamic transmis-
sion model capturing the pairwise interactions of two
influenza A strains, A/H1N1 and A/H3N2, and two in-
fluenza B lineages, B/Yamagata and B/Victoria [26]. In-
teractions between the strains were assumed to occur
via both natural and vaccine-conferred partial cross-
reactive immunity. We assumed that influenza A to B
cross-protection is negligible, and modeled only pairwise
cross-protection between the two A strains, and between
the two B lineages, respectively. The overall structure is
thus of a pair of essentially independent two-strain
models. Age-dependent contact patterns were specified
using a contact matrix [27, 28] to calculate the force of
infection. This model was run over a 10-year time hori-
zon, following a 30-year burn-in period. A detailed
description of model structure, assumptions and calibra-
tion methodology are given in [26]
The model’s structure makes it capable of reproducing
the key transmission dynamics of seasonal influenza,
specifically herd immunity, strain interaction, waning
immunity and dependence on population contact pat-
terns. A small background contribution to the force of
infection (corresponding to case importation) varies ran-
domly from season to season, (separately for influenza A
and B), thus rendering individual simulations stochastic.
Model parameters were fit using an approximately
Bayesian computation (ABC) parameter fitting scheme
[29], similar to those used previously for fitting human
Thommes et al. BMC Infectious Diseases  (2015) 15:465 Page 2 of 14
papillomavirus models [30, 31]. The model was cali-
brated using, as fitting targets, the United States of
America (US) unvaccinated (natural) influenza attack
rates and year-to-year relative amount of influenza A
compared to influenza B [21, 32]. Calibrating on only
the unvaccinated population removes direct dependence
of the attack rate on the efficacy and uptake of influenza
vaccine in the population, though it is still coupling
through herd immunity; for this reason the season-by-
season vaccine uptake in the US population was also
included in the calibration. Further details of the calibra-
tion process are given in [26]. The resultant posterior
distribution of sets of influenza natural history parame-
ters was then applied to the populations of two countries
considered in this analyses - Canada and the UK. The
detailed methodology of the calibration of this model is
described in Thommes et al. [26].
Model input data and assumptions
Baseline demographic, cost, utility and vaccine-related
input parameters for the dynamic transmission model
were obtained from locally available databases and pub-
lished literature, details of which are described below
(for details see Additional file 1).
Intervention strategy
In Canada, where TIV is predominantly used in provin-
cial or territorial public programs, we evaluated a full
switch from TIV to QIV in individuals of all age groups,
at the current nationwide vaccine uptake level (2014).
To capture current recommendations and practice in
the UK [18, 19], we evaluated two strategies: Children
aged 2–17 years who receive the live-attenuated influ-
enza vaccine (LAIV), while individuals of ages 18 and
above receive TIV. In this analysis, the latter age group
undergoes a switch from TIV to QIV and children aged
2–17 years undergo an analogous switch from the triva-
lent formulation of LAIV to the quadrivalent formula-
tion of LAIV (QLAIV). Given that the pediatric
vaccination program in the UK is currently in its rollout
phase, two different vaccination uptake scenarios in chil-
dren (denoted UK1 and UK2) were evaluated.
Demographics
Demographic data, including birth and all-cause mortal-
ity rates for Canada were based on the year 2012 and
were obtained from the Statistics Canada’s CANSIM on-
line database [33]. For the UK, demographic data, birth
and all-cause mortality rates were obtained from the Of-
fice of National Statistics (data based on mid-2010 popu-
lation estimates) [34]. Age-dependent contact patterns
specific to Canada are unavailable and hence data from
the US were used [35]. For the UK, the relevant contact
matrix from Mossong et al. (physical and non-physical
contacts) was used [36]. The UK matrix is in terms of
number of daily contacts, whereas the US matrix is in
terms of daily minutes of contact; since the natural his-
tory parameter calibration was performed using the US
matrix, the UK matrix had to be converted. We did this
assuming a linear relationship between daily minutes
and the number of contacts, with the scaling factor
chosen to yield the same dominant eigenvalue for UK
matrix as for the US.
Outcome probabilities
Four outcomes of symptomatic influenza were consid-
ered in this analysis – general practitioner (GP) visit,
emergency room (ER) visit, hospitalization and death. In
the absence of available Canada-specific outcomes prob-
abilities, the US-derived values of Molinari et al. [37] for
GP visits, hospitalization and death were used. Probabil-
ity of an ER visit was derived from the probability of
hospitalization using a fixed ratio between the two quan-
tities [24]. For the UK, these outcome probabilities were
obtained from Turner et al. [32] (GP visit), Tappenden
et al. [38] (ER visit and hospitalization) and Meier et al.
[39] (death) (Additional file 1, see Table 1.1, 1.2).
Utilities
Age-specific life-expectancy was obtained from the Life
Tables and Interim Life Tables for Canada [40, 41] and
the UK [42], respectively. Baseline utilities for Canada
and the UK were obtained from Mittmann et al. [43]
and Tappenden et al.[38], respectively (Additional file 1,
see Table 1.3). For Canada, quality-adjusted life-year
(QALY) loss per uncomplicated case and medically-
attended influenza case were obtained from Tarride et
al. [24] and Sander et al. [44], respectively. For the UK,
these quantities were obtained from Tappenden et al.
[38] (Additional file 1, see Table 1.4).
Vaccine uptake
Vaccine uptake rates for Canada in children aged 6–23
months and 2–11 years were obtained from Moran et al.
[45] and for individuals aged ≥12 years from Statistics
Canada’s CANSIM online database [33] (Additional file
1, see Table 1.5). For the UK, individuals, clinically at-
risk (ages 18–64 years and 65+ years) are vaccinated and
a universal childhood vaccination program for children
of ages 2–17 years is being phased in as of 2013. Given
the ongoing changes in child vaccine uptake, we thus
considered two scenarios (UK1 and UK2) which differ
only in the vaccine uptake in children 2–17 years of age
(Additional file 1, see Table 1.6).
Vaccine efficacy and adverse events
Vaccine efficacy against influenza A was assumed to be
identical for both TIV and QIV. The average efficacy of
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TIV against influenza A was estimated from three
Cochrane reviews in healthy children [46] adults [47]
and elderly individuals [48]. This is also supported on
the basis of non-inferiority data of QIV and TIV from a
vaccine effectiveness study comparing both vaccines
[49]. TIV efficacy against influenza B for both a lineage
match and mismatch was obtained from a meta-analysis
of clinical trials [8]. QIV efficacy against both lineages
of influenza B was assumed to always be that of TIV
against the matched B lineage. Due to limitations in
LAIV influenza B match-mismatch efficacy data in
children of ages 3 and above [8], identical efficacies
were used for matched LAIV, mismatched LAIV and
QLAIV for ages 3–17 years (Additional file 1, see
Table 1.7, 1.8). Vaccine-conferred protection against
both influenza A and B was assumed to last only one
year on average [50].
Data from clinical trials show that QIV and TIV have
similar safety profiles [13, 15, 49]. Moreover, with both
vaccines the occurrence of adverse events was low, and
when present transient in nature [38]. Thus we excluded
this parameter in the model.
Costs associated with resource use
All costs are reported in the national currencies of the two
countries, i.e. the Canadian dollar ($) and Great British
Pound (£). The reference year for costs was 2013. For
Canada, when costs were unavailable for 2013, they were
inflation-adjusted to 2013 using the Canadian Consumer
Price Index [33]. In this analysis we considered the payer
perspective and therefore only direct medical costs were in-
cluded. Costs per GP and ER visit for Canada were ob-
tained from Tarride et al. [24] For cost per hospitalization,
data from the Canadian Institute for Health Information
(CIHI) Patient Cost Estimator tool was used [51]. UK cost
data was obtained using multiple sources, analogous to Van
Bellinghen et al. [22] (Additional file 1, see Table 1.9).
Vaccination costs
For Canada, the blended price of TIV was estimated as an
average from published sources at $6.18 per dose [24, 44,
52]. For the UK, the price of TIV was calculated as a
weighted average of all TIV available on the UK market and
estimated at £6.39 per dose [53]. For QIV in the UK, the list
price of £9.94 per dose was used [54]. This constitutes a
TIV-QIV price difference of a factor of ~1.56; a hypothet-
ical QIV price for Canada of $9.61 per dose was derived as-
suming the same relative price difference. Finally, for LAIV
and QLAIV, modeled only in the UK scenarios, the list
price of £14.00 per dose was used [54]. For Canada, cost of
vaccine administration is taken to be at $3.78 [44]. In the
UK, vaccination was assumed to take place as part of a
regular GP visit, and thus to incur no additional vaccine ad-
ministration cost (Additional file 1, see Table 1.9).
Analyses
Base case analyses
Health and cost outcome measures resulting from the
two vaccination strategies (QIV and TIV) and the differ-
ence between QIV and TIV are estimated. For Canada,
calculations were performed using a discount rate of 5 %
per year for monetary and utility costs as well as out-
comes [55]. In the case of the UK, a discount rate of
3.5 % per year was applied to costs and outcomes [56]
(see Additional file 1, Table 1.10). To determine the
cost-effectiveness of implementing a switch from TIV to
QIV, the incremental cost-utility ratio (ICUR) was calcu-
lated from the third party payer perspective. Cost-
effectiveness thresholds of $40,000–50,000 per QALY
gained [44] and £20,000 per QALY gained [57] were as-
sumed for Canada and the UK, respectively.
To simulate the impact of a switch from TIV to QIV
in Canada and the UK, we performed for each country a
set of 1,000 pairs of simulations with the influenza nat-
ural history input parameters for each pair drawn from
the aforementioned posterior parameter sets. Each pair
consists of one simulation in which a switch from TIV
to QIV occurs in the 2014–2015 season (the interven-
tion), and another in which the use of TIV is continued
(the comparator). For each simulation, results were re-
corded from the beginning of the 2014–2015 season to
the end of the 2023–2024 season, i.e. over ten seasons.
Seasonal averages of influenza infections were estimated
for this time period.
Deterministic sensitivity analyses
In each scenario evaluated, the distributions of outcomes
produced by our ensemble of 1,000 simulation pairs re-
flects both our uncertainty about the true natural history
parameters of influenza, and the stochastic nature of the
individual simulations. In other words, our ensemble of
simulations constitutes a probabilistic sensitivity analysis
(PSA) on natural history parameters of influenza as well
as on the variability of influenza seasons.
We also performed a combination of univariate and
multivariate sensitivity analyses to investigate the sensitiv-
ity of the model outcome, specifically, of the point esti-
mate of cost per QALY gained (i.e. the ICUR) estimated
by the model. Different parameters were varied:
▪ QIV price per dose (Canada and UK) to the upper
and lower limits of their respective range values, see
Additional file 1, Table 1.9.
▪ QALY loss (one-sided analysis; for the lower bound,
we neglected all non-death QALY loss),
▪ All breakthrough infection outcomes: If vaccination
reduces the severity of influenza in breakthrough
infections (i.e. infections of people who are
vaccinated within the current season), this has the
Thommes et al. BMC Infectious Diseases  (2015) 15:465 Page 4 of 14
potential to reduce the benefit of QIV relative to
TIV. In this sensitivity analysis (multivariate and
one-sided), the most extreme possible scenario was
considered, wherein TIV and QIV both have 100 %
efficacy against all influenza-associated outcomes (GP
visit, ER visit, hospitalization and death). This was
done by simultaneously setting all the corresponding
outcomes probabilities to zero for breakthrough
infections.
▪ Probability of hospitalization (P_hosp), breakthrough
infection: Like all breakthrough infection outcomes
above, but with 100 % vaccine efficacy only against
hospitalization. Vaccine efficacy against all other
outcomes is as in the base case, equal to the vaccine
efficacy against infection.
▪ Outcomes probabilities: Multivariate analysis with all
outcome probabilities varied simultaneously at their
95 % confidence interval (CI) lower and upper limits
(see Additional file 1, Table 1.1, Table 1.2).
▪ Discount rate: For Canada (base case = 5.0 %) and the
UK (base case = 3.5 %) one-sided sensitivity analysis
using 3.5 % and 5.0 % discount rates, respectively,
and,
▪ GP cost, ER cost, and hospitalization cost: For
Canada and the UK to the upper and lower limits of





Overall, in an average influenza season, our model pre-
dicts that a nationwide switch from TIV to QIV would
prevent in Canada, 4.6 % (n = 135,538) of influenza
Table 1 Overall mean health and cost outcomes for Canada
TIV QIV Difference (TIV vs. QIV) % Difference
Average influenza-related outcomes per season, n (95 % CI)
Cases 2,933,460 (2,532,276; 3,351,695) 2,797,922 (2,392,853; 3,199,681) −135,538 (−228,154;
−76,677)
−4.6 (−7.7; −2.7)
GP visits 1,066,568 (921,034; 1,218,892) 1,014,368 (868,298; 1,160,118) −52,200 (−88,460; −29,055) −4.9 (−8.2; −2.8)
ER visits 59,704 (51,257; 68,574) 56,309 (47,987; 64,721) −3,395 (−5,907; −1,731) −5.7 (−9.7; −3.0)
Hospitalizations 32,986 (28,319; 37,886) 31,110 (26,512; 35,757) −1,876 (−3,264; −956) −5.7 (−9.7; −3.0)
Deaths 4,836 (4,114; 5,606) 4,508 (3,811; 5,230) −328 (−584; −156) −6.8 (−11.9;
−3.2)
Average costs per season, $ (95 % CI)
Vaccination $114,269,815 (113,818,022; 114,795,606) $153,621,770 (153,014,388; 154,328,631) $39,351,954 (39,196,367; 39,533,025)
GP visits $45,574,462 (39,355,763; 52,083,266) $43,343,948 (37,102,387; 49,571,823) -$2,230,514 (−3,779,889; −1,241,510)
ER visits $13,337,288 (11,450,298; 15,318,666) $12,578,851 (10,719,802; 14,457,926) -$758,437 (−1,319,645; −386,684)
Hospitalization $120,689,432 (103,441,040; 138,855,265) $113,695,532 (96,748,864; 130,839,986) -$6,993,900 (−12,204,664; −3,525,203)
Total payer
costs
$293,870,997 (268,805,179; 320,376,234) $323,240,101 (298,328,487; 348,108,942) $29,369,104 (22,016,160; 34,131,5416)
Total costs, 2014–24: 5 % discounted, $ (95 % CI)
Vaccination $868,017,693 (864,552,580; 872,000,633) $1,166,943,465 (1,162,285,045;
1,172,298,039)
$298,925,772 (297,732,465; 300,297,407)
GP visits $347,201,538 (298,121,148; 398,164,181) $329,329,994 (280,856,904; 378,138,361) $-17,871,544 (−29,416,959; −9,870,111)
ER visits $101,255,332 (86,543,184; 116,554,469) $95,274,727 (80,828,208; 109,823,373) $-5,980,605 (−10,120,952; −3,025,115)








QALYs lost, n (95 % CI)
Per season 68,980 (59,036; 79,436) 64,930 (55,206; 74,837) −4,050 (−7,076; −2,033)
Total 522,596 (446,330; 601,554) 490,805 (414,820; 567,537) −31,791 (−54,079; −15,845)
LYs lost, n (95 % CI)
Per season 45,675 (38,909; 52,852) 42,732 (36,152; 49,573) −2,944 (−5,215; −1,417)
Total 344,912 (293,245; 398,169) 322,013 (270,885; 374,069) −22,899 (−39,878; −10,871)
Note: A negative value for the difference denotes outcomes prevented; GP, general practitioner; ER, emergency room; QALYs, quality-adjusted life years; LYs,
life years
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Table 2 Overall mean health and cost outcomes for the UK
UK1
TIV/LAIV QIV/QLAIV Difference (TIV/LAIV
vs QIV/QLAIV)
% Difference
Average influenza-related outcomes per season, n (95 % CI)
Cases 6,175,473 (5,348,157; 7,095,022) 6,086,718 (5,244,706; 6,981,581) −88,755 (−153,607; −46,761) −1.4 (−2.5; −0.8)
GP visits 1,477,243 (1,276,226; 1,698,398) 1,454,327 (1,249,078; 1,672,087) −22,917 (−39,758; −12,127) −1.6 (−2.7; −0.8)
ER visits 45,688 (39,471; 52,528) 44,979 (38,631; 51,714) −709 (−1,230; −375) −1.6 (−2.7; −0.8)
Hospitalizations 71,740 (62,217; 82,455) 70,690 (61,026; 81,103) −1,050 (−1,824; −553) −1.5 (−2.5; −0.8)
Deaths 5,366 (4,609; 6,207) 5,136 (4,372; 5,941) −230 (−424; −107) −4.3 (−7.5; −2.0)
Average costs per season, £ (95 % CI)
Vaccination £142,869,897 (142,132,194; 143,838,565) £173,690,646 (172,847,546; 174,801,973) £30,820,749 (30,714,458; 30,964,151)
GP visits £54,658,003 (47,220,348; 62,840,730) £53,810,083 (46,215,893; 61,867,225) -£847,920 (−1,471,032; −448,693)
ER visits £6,167,872 (5,328,571; 7,091,250) £6,072,188 (5,215,223; 6,981,395) -£95,683 (−165,998; −50,633)
Hospitalization £316,143,107 (273,230,094; 363,500,069) £310,054,168 (266,192,382; 356,545,209) -£6,088,939( −10,684,477; −3,156,736)
Total payer
costs
£519,838,878 (469,625,943; 576,456,567) £543,627,085 (491,853,288; 598,787,408) £23,788,206 (18,451,500; 27,182,411)






GP visits £449,966,551 (390,148,320; 516,657,013) £442,621,741 (381,366,507; 508,088,148) -£7,344,811 (−12,406,117; −3,925,542)













QALYs lost, n (95 % CI)
Per season 138,681 (119,774; 159,443) 135,415 (116,128; 155,866) −3,266 (−5,749; −1,616)
Total 1,143,215 (990,661; 1,314,381) 1,115,337 (958,023; 1,283,316) −27,878 (−48,670; −13,753)
LYs lost, n (95 % CI)
Per season 67,761 (58,243; 78,145) 65,340 (55,700; 75,446) −2,421 (−4,407; −1,150)
Total 560,869 (482,171; 647,615) 540,396 (459,999; 623,573) −20,473 (−37,239; −9,741)
UK2
TIV/LAIV QIV/QLAIV Difference (TIV/LAIV vs QIV/
QLAIV)
% Difference
Average influenza-related outcomes per season, n (95 % CI)
Cases 5,335,431 (4,663,367; 6,094,108) 5,237,644 (4,563,870; 5,976,162) −97,787 (−167,789; −53,233) −1.8 (−3.0; −1.0)
GP visits 1,279,954 (1,116,137; 1,463,587) 1,254,916 (1,091,268; 1,432,823) −25,038 (−42,527; −13,756) −2.0 (−3.2; −1.1)
ER visits 39,586 (34,520; 45,266) 38,812 (33,751; 44,314) −774 (−1,315; −425) −2.0 (−3.2; −1.1)
Hospitalizations 61,812 (54,111; 70,575) 60,658 (52,902; 69,153) −1,154 (−1,992; −626) −1.9 (−3.1; −1.1)
Deaths 4,772 (4,146; 5,483) 4,538 (3,921; 5,202) −234 (−410; −116) −4.9 (−8.3; −2.5)
Average costs per season, £ (95 % CI)
Vaccination £171,724,730 (170,737,027; 172,880,105) £202,522,845 (201,431,528; 203,801,765) £30,798,116 (30,696,168; 30,920,847)
GP visits £47,358,314 (41,297,066; 54,152,709) £46,431,902 (40,376,915; 53,014,460) -£926,412 (−1,573,508; −508,968)
ER visits £5,344,140 (4,660,159; 6,110,852) £5,239,599 (4,556,325; 5,982,406) -£104,541 (−177,562; −57,434)
Hospitalization £274,233,102 (239,080,248; 313,959,886) £267,724,197 (232,618,317; 305,657,406) -£6,508,906 (−11,183,958; −3,502,201)
Total payer
costs
£498,660,286 (457,399,436; 545,711,073) £521,918,543 (480,857,526; 567,317,462) £23,258,257 (17,987,595; 26,732,485)
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cases, 4.9 % (n = 52,200) GP visits, 5.7 % (n = 3,395) ER
visits, 5.7 % (n = 1,876) hospitalizations and 6.8 % (n =
328) deaths (Table 1). In the UK1 scenario (i.e. vaccine
uptake among children as of 2013), a switch from TIV
to QIV is expected to prevent 1.4 % (n = 88,755) influ-
enza cases, 1.6 % (n = 22,917) GP visits, 1.6 % (n = 709)
ER visits, 1.5 % (n = 1,050) hospitalizations and 4.3 % (n
= 230) deaths. In the UK2 scenario (higher than UK1;
projected target vaccine uptake among children in the
future), switching from the trivalent to the quadrivalent
formulation is expected to have a slightly higher impact
than that observed with the UK1 scenario. Under the as-
sumptions of the UK2 scenario, the model predicts that
a switch from the trivalent to the quadrivalent formula-
tion would prevent 1.8 % (n = 97,787) influenza cases,
2.0 % (n = 25,028) GP visits, 2.0 % (n = 774) ER visits,
1.9 % (n = 1,154) hospitalizations and 4.9 % (n = 234)
deaths (Table 2).
Outcomes results are also reported in age-stratified
form for age groups 0–4, 5–19, 20–49, 50–64, 65–74,
75–84 and 85–99 years; see Additional file 2, Additional
file 3. This presentation provides additional insight. For
example, in Canada the percentage of deaths prevented
across all ages is higher than that of cases prevented,
and in the UK the difference is even more pronounced.
Now the case fatality ratio for influenza i.e. probability
Table 2 Overall mean health and cost outcomes for the UK (Continued)






GP visits £390,019,191 (338,972,997; 445,806,414) £382,011,087 (331,356,732; 436,393,837) -£8,008,104 (−13,328,069; −4,445,418)













QALYs lost, n (95 % CI)
Per season 121,040 (105,258; 138,570) 117,603 (102,122; 134,418) −3,437 (−5,970; −1,802)
Total 998,215 (867,812; 1,140,983) 968,900 (839,411; 1,106,335) −29,315 (−49,909; −15,593)
LYs lost, n (95 % CI)
Per season 59,931 (51,974; 68,794) 57,448 (49,677; 65,930) −2,484 (−4,309; −1,247)
Total 496,291 (429,909; 568,923) 475,295 (409,468; 545,073) −20,996 (−36,237; −10,647)
Note: A negative value for the difference denotes outcomes prevented; GP, general practitioner; ER, emergency room; QALYs, quality-adjusted life years; LYs,
life years
Fig. 1 Comparison of a typical TIV-QIV pair of model simulations (example of Canada). Note: The seventh and tenth influenza B peaks are actually
slightly higher with QIV than with TIV. This is because the model is stochastic; TIV and QIV versions diverge so there is no real 1:1 correspondence
between seasons after the first season in which QIV is introduced; Since TIV and QIV have identical efficacy against influenza A, the evolution of
influenza A incidence with the TIV and QIV is identical between the pair of simulations
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Fig. 2 Distribution of mean influenza-related outcomes per season (a) Canada (b) UK. Note: Outcomes are presented for TIV (comparator) and
QIV (intervention) and mean outcomes prevented resulting from a switch from TIV to QIV (prevented)
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of death due to influenza rises sharply in individuals of
ages above 65 years in both countries (Additional file 1,
Table 1.1 and Table 1.2), thus the percentage of overall
deaths prevented depends most strongly on the percent-
age of cases prevented in the elderly. Indeed, in both
Canada and the UK scenarios, the percentage of cases
prevented increases with age similar to vaccine uptake.
This features more strongly in the UK where healthy in-
dividuals aged 18–64 years are not part of the public
vaccination program.
A typical example of one pair of Canadian simulations,
showing the impact of switching from TIV to QIV, is
shown in Fig. 1. The distribution of model results for
mean outcomes per season across all age groups with
TIV, QIV and the difference between the two interven-
tions per simulation pair, for Canada and the UK (1,000
model results each), are shown in Fig. 2.
Cost-effectiveness analysis
In Canada, discounting at 5 %, a switch from TIV to
QIV would result in costs of $224, $588, $9,407, $17,206
and $10,1215 per influenza case, GP visit, ER visit,
hospitalization and death averted, respectively. Costs per
QALY and life-year (LY) gained were estimated as
$7,961 (95 % CI: $3,080–$16,320) and $11,211 (95 % CI:
$4,181–$23,815), respectively (Table 3).
For the UK (scenarios UK1/UK2), discounting at
3.5 %, a switch from TIV to QIV would result in costs of
£282/£250, £1,100/£979, £35,568/£31,641, £23,929/
£21,207, and £117,428/£110,496 per influenza case, GP
visit, ER visit, hospitalization and death averted, respect-
ively. Discounted costs per QALY and LY gained were
estimated at £7,989 (95 % CI: 3,132–16,318)/£7,324
(95 % CI: 2,937–14,044) and £11,081 (95 % CI:
4,135–23,186)/£10,364 (95 % CI: 4,029–20,588), re-
spectively (Table 4).
The model results for the ICUR are presented as a
cost-effectiveness acceptability curve, which shows, as a
function of the adopted cost-effectiveness threshold, the
probability that a switch from TIV to QIV would be
cost-effective. For Canada, considering a threshold of
$40,000–50,000 per QALY gained [44], a switch from
TIV to QIV is predicted to have a 100 % probability of
cost-effectiveness. For the UK, considering a threshold
of £20,000 per QALY gained [57], the model predicts a
probability of cost-effectiveness greater than 99 %
(Fig. 3).
Deterministic sensitivity analyses
Deterministic sensitivity analyses for both the countries
indicate that among the model parameters varied, the
modelled ICUR is most sensitive to the chosen range of
QIV price per dose, outcome probabilities (varied simul-
taneously), to whether QALY loss due to non-fatal
influenza is taken into account, and to a hypothetical ex-
treme case scenario in which breakthrough infections
never result in a GP visit, ER visit, hospitalization or
death, regardless of the type of vaccine used. For
Canada, the ICUR varies from a minimum of $5,000 per
QALY (lower QIV price) to a maximum of $12,600 per
QALY (higher QIV price), while for the UK it varies
from a minimum of £4,000 per QALY (high values for
all outcomes rates) to a maximum of £14,200 per QALY
(QALY loss due to non-fatal influenza neglected) (Fig. 4).
Comparison to the accepted cost-effectiveness thresh-
olds of $40,000–$50,000 per QALY gained and £20,000
per QALY gained in Canada and the UK respectively,
suggests a high likelihood of cost-effectiveness in both
countries, especially Canada, notwithstanding uncer-
tainty in rates of outcomes and costs.
Table 3 Modeled ICURs for Canada (discounted, 5 %)
Category Mean value (95 % CI)
Cost per case averted $224 (94; 419)
Cost per GP visit averted $588 (243; 1120)
Cost per ER visit averted $9,407 (3,678; 19,086)
Cost per hospitalization averted $17,026 (6,658; 34,546)
Cost per death averted $101,215 (37,429; 216,888)
Cost per QALY gained $7,961 (3,080; 16,320)
Cost per LY gained $11,211 (4,181; 23,815)
Note: GP, general practitioner; ER, emergency room; QALY, quality-adjusted life
year; LY, life year
Table 4 Modeled ICURs for the UK (discounted, 3.5 %)
Outcomes, 3.5 % discount Mean value (95 % CI)
UK1
Cost per case averted £282 (118; 538)
Cost per GP visit averted £1,100 (456; 2,113)
Cost per ER visit averted £35,568 (14,729; 68,327)
Cost per hospitalization averted £23,929 (9,934; 45,494)
Cost per death averted £117,428 (43,067; 246,342)
Cost per QALY gained £7,989 (3,132; 16,318)
Cost per LY gained £11,081 (4,135; 23,186)
UK2
Cost per case averted £250 (105; 461)
Cost per GP visit averted £979 (404; 1,821)
Cost per ER visit averted £31,641 (13,069; 58,892)
Cost per hospitalization averted £21,207 (8,909; 39,220)
Cost per death averted £110,496 (42,719; 221,654)
Cost per QALY gained £7,324 (2,937; 14,044)
Cost per LY gained £10,364 (4,029; 20,588)
Note: GP, general practitioner; ER, emergency room; QALY, quality-adjusted life
year; LY, life year
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Discussion
This analysis aimed to assess the potential impact of
switching from TIV to QIV over ten seasons in Canada
and the UK. The dynamic transmission model in this
analysis provides a detailed, age- and strain or lineage-
stratified representation of influenza dynamics, cali-
brated to surveillance data.
The model estimates that implementing a switch from
TIV to QIV in both Canada and the UK would result in
moderate reductions in the number of influenza cases and
influenza-associated outcomes (GP and ER visits,
hospitalizations and deaths). Though both countries have
broadly similar demographic characteristics, we observed
a significantly greater relative impact from the switch in
Canada compared to the UK. The difference stems princi-
pally from vaccine uptake: While most Canadian prov-
inces have universal influenza immunization programs
(free vaccination for ages 6 months and above), the tar-
geted vaccination program in the UK, although currently
expanding to cover children, still leaves healthy adults
aged 18–64 uncovered, resulting in significantly lower up-
take in that age group as compared to Canada [33, 45].
Fig. 3 Cost-effectiveness acceptability curves (a) Canada (b) UK‡. Note: QALY, quality-adjusted life-year; Cost-effectiveness threshold for Canada
and UK are $40,000–50,000 and £20,000 per QALY gained, respectively; ‡Figure presented for the UK is based on Scenario UK1, UK2 is very similar
(data not shown)
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Despite a net increase in payer cost associated with
the switch from TIV to QIV at the assumed QIV prices,
the use of QIV is projected to be highly cost-effective in
both countries, with an ICUR point estimate of $7,961,
£7,989 and £7,324 per QALY gained in Canada and in
the two UK scenarios, respectively, far below each coun-
try’s cost-effectiveness threshold. This conclusion is
shown to be robust against uncertainty in the natural
history parameters of influenza (as expressed in the
cost-effectiveness acceptability curves, Fig. 4) in both
settings, albeit more strongly so in Canada. Separate de-
terministic sensitivity analysis suggests it is also robust
against uncertainty in costs and outcomes rates, again
specifically in Canada.
A switch from TIV to QIV may carry additional bene-
fits beyond those modeled here. Even though we have
conservatively assumed that all vaccinated immunity
only lasts one year on average, the slower antigenic drift
of influenza B may result in some carry-over of influenza
B protection to subsequent seasons, thus further
Fig. 4 Deterministic sensitivity analyses (a) Canada (b) UK‡. Note: The grey vertical line corresponds to all the uncertain parameters being at their
respective base values. The red segments of the bars correspond to result values increasing the base case ICUR and the blue segments of the
bars correspond to result values decreasing the base case ICUR; ‡Figure presented for the UK is based on Scenario UK1, UK2 is very similar (data
not shown); ER, emergency room; GP, general practitioner, QIV, quadrivalent influenza vaccine; QALY, quality-adjusted life-year
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increasing the benefit of QIV relative to TIV [2]. Also,
since vaccination with QIV is expected to result in fewer
mismatched seasonal vaccine campaigns, its adoption
may result in improved public perception of influenza
vaccination, in turn translating into higher vaccine up-
take [2].
Only a handful of studies have so far modeled the im-
pact of switching from TIV to QIV on a country scale,
in the US [18, 19] and the UK [20, 21, 23]. These studies
have reported broadly similar findings to ours, of cost-
effectiveness across a broad range of QIV prices. How-
ever to our knowledge, there are thus far no published
TIV-QIV studies utilizing a dynamic model, and none at
all for Canada. Canadian studies of a different influenza
vaccine intervention do exist as a basis for comparison,
namely the transition in 2000 of the province of Ontario
from targeted to universal immunization. A health eco-
nomic study by Sander et al. [44], utilizing the results of
an ecological study by Kwong et al. [58] (which served
as a test case for the model we use here [26]), estimated
the cost-effectiveness of Ontario’s transition at $12,154
per QALY gained. Our work here thus suggests that the
cost-effectiveness of a TIV-QIV switch is comparable to
that of a targeted-universal switch.
Our model was chosen for its ability to reproduce key
elements of influenza dynamics: herd immunity, waning
immunity, seasonality, age-specific contact patterns, and,
critically for the problem studied here, the interplay of
multiple influenza strains and influenza B lineages. How-
ever, like any model, it had limitations. Stratification of
the population was only by age; healthy and at-risk parts
of the population were not separately tracked. As de-
scribed in [26], calibration of the natural history parame-
ters of influenza was performed using the US as a
setting, thus making the assumption that these differ
negligibly between the US, Canada and the UK. It should
be emphasized that the distribution of outcomes ob-
tained through the calibration procedure (effectively a
probabilistic sensitivity analysis on influenza natural his-
tory parameters) does not encapsulate uncertainty about
the comparability of US to Canadian and UK influenza
natural history. Due to the absence of Canadian data, US
outcomes probabilities were used for Canada. Limita-
tions in available LAIV influenza B match/mismatch ef-
ficacy data caused the LAIV and QLAIV modelled in the
UK scenarios differ little in efficacy. Finally, we did not
consider adverse events due to vaccination in this ana-
lysis. But given that both vaccines have similar safety
profiles, this assumption is justified as it would not im-
pact the model result.
Conclusions
Our findings predict that a switch from TIV to QIV is a
highly cost-effective intervention to reduce the burden
of influenza in both Canada and the UK, and thus sug-
gest such a switch as a public health policy priority in
both settings.
Additional files
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